Dan Beney Named Bluegrass Vascular Vice President of Sales

Bluegrass Vascular Technologies, a private medical technology company focused on innovating lifesaving devices and methods for vascular access procedures, today announced Dan Beney has joined the company’s executive team as Vice President of Sales.

In this role, Dan Beney will lead the expansion of the company’s sales efforts to drive the utilization of the Surfacer® Inside-Out® Access Catheter System to facilitate central venous access for patients with venous obstructions.

Mr. Beney has more than 35 years of experience in senior sales leadership positions within the medical device industry. Prior to joining Bluegrass Vascular, Dan served as Vice President of Sales at Avenu Medical (acquired by Medtronic), Vice President of Focal Therapeutics (acquired by Hologic), Vice President of International Sales and Business Development at Cianna Medical (acquired by Merit Medical), Vice President of Sales and Marketing for Intact Medical Corporation (acquired by Medtronic), and as the National Sales Manager for the Breast Care division of Johnson & Johnson (formerly Biopsys Medical). In addition, Dan has also held executive management positions with Conceptus, Neurometrix and Scimed Life Systems. Dan earned his Bachelor of Arts degree in Advertising from Michigan State University.

“It’s exciting to join a team with such innovative, life-saving technology,” Beney said. “Bluegrass Vascular’s commitment to improving the patient outcomes and the work the company has done to date to develop and establish the Surfacer System has created a solid foundation for future growth.”

“Dan is a results-driven leader in the medical device industry who brings extensive experience scaling teams and driving the adoption of innovative technologies,” stated Gabriele Niederauer, Ph.D., CEO and President of Bluegrass Vascular. “His sales leadership, professional relationships with key thought leaders, and his strong background in building top performing sales teams will help to accelerate the company’s growth.”

About the Surfacer® Inside-Out® Access Catheter System: The Surfacer System is designed to reliably, efficiently and repeatedly gain central venous access by inserting the Surfacer System through the right femoral vein and navigating it up through the patient’s venous system with an exit point in the right internal jugular vein, the optimal location for placing a central venous catheter.

This proprietary Inside-Out approach allows for the placement and maturation of permanent arteriovenous access options that are associated with improved patient outcomes and reduced cost of care for both hospitals and hemodialysis providers.

The Surfacer System has received FDA De Novo device clearance in the US and is CE
marked in Europe. The device is currently distributed in North America and Europe by Merit Medical, a global manufacturer and distributor of medical devices.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.